MV-CHIKV Chikungunya Vaccine Clinical Trial Begins
A clinical trial of an experimental vaccine to prevent infection with chikungunya virus is now enrolling healthy adult volunteers at ...
Tag: NIAID
Nonclinical Services for Development of Interventional Agents for Infectious Diseases
The National Institute of Allergy and Infectious Diseases (NIAID) Division of Microbiology and Infectious Diseases (DMID) is seeking proposals for ...
Advancing Therapeutic Discovery for Select Resistant Gram-Negative Bacteria
In response to the threat presented by increasing numbers of infections caused by antimicrobial–resistant (AR) and multidrug-resistant (MDR) Gram-negative bacterial ...
Omnibus BAA for Biodefense, Radiation Exposure Countermeasures
The National Institute of Allergy and Infectious Diseases (NIAID) will be soliciting proposals under a new Omnibus Broad Agency Announcement ...
NIAID-Backed Phase 1b Study to Evaluate Broad-Spectrum Antiviral for Dengue
A Phase 1b multiple ascending dose study to evaluate the safety and tolerability of UV-4B has been initiated by Emergency ...
HHS Releases 2016 PHEMCE Strategy and Implementation Plan
The 2016 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan (SIP), released this week by the U.S. Department ...
Radiation Illness Countermeasure Advances into Second Cohort of Dose Selection Study
Pluristem Therapeutics on Dec. 6 announced a milestone in its development program for PLX-R18, which is being evaluated as a ...
NIAID Awards Biodefense Countermeasure Contracts
National Institute of Allergy & Infectious Diseases (NIAID) has awarded new contracts under a Broad Agency Announcement (BAA) for Development ...
Study: Malaria Parasite Improves Odds of Surviving Ebola
A collaboration of research groups led by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have published ...
Handicapping Ebola to Buy Immune System Time to Respond
The Ebola virus acts fast. The course of infection, from exposure to recovery, or death, can take as little as ...
Clinical Research Collaborations to Meet Emerging Biothreats
The National Institute of Allergy and Infectious Diseases (NIAID), Division of Clinical Research (DCR), rapidly deploys administrative and technical research ...
NIAID Exercises Option on Soligenix Radiation Countermeasure
The National Institute of Allergy and Infectious Diseases (NIAID) has exercised a funding option with Soligenix, Inc. to advance preclinical development ...
NIAID Exercises Option on Thermostable Ricin Vaccine Contract
Soligenix, Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to advance ...
BAA – Medical Countermeasures for Priority Pathogens
The National Institute of Allergy and Infectious Diseases (NIAID) has released a new Broad Agency Announcement (BAA) to support development ...
Soligenix, Emergent BioSolutions Announce Ricin Vaccine Agreement
Soligenix, Inc. this week announced that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, ...
Phase I Clinical Trial Unit for Infectious Disease Therapeutics
The National Institute of Allergy and Infectious Diseases (NIAID) has announced new contract awards to support the Phase I Clinical ...
RFP – Malaria Vaccine Human Clinical Trials
The National Institute of Allergy and Infectious Diseases (NIAID) intends to solicit proposals for contracts entitled "Operation of a Facility ...
NIAID/GSK Ebola Vaccine Prompts Immune Response
The candidate Ebola vaccine developed collaboratively by scientists at NIAID’s Vaccine Research Center and GlaxoSmithKline (GSK) was shown to be ...
Rare and Emerging Viral Disease Impact on Special Populations
The National Institute of Allergy and Infectious Diseases (NIAID) has a requirement for the development of therapeutic strategies for select ...
NIAID/GSK Experimental Ebola Vaccine Appears Safe
A 39-year-old woman, the first participant enrolled in VRC 207, receives a dose of the investigational ...
